Skip to content
Clinical Trials – home

RIZOLIPASE: A Pancreatic Enzyme for Patients After Gastrectomy

1 / 1
trials open to patients / all trials
1+
Countries

In short

In recent clinical trials, researchers are investigating the potential benefits of Rizolipase, a pancreatic enzyme, for patients who have undergone gastrectomy (removal of part or all of the stomach). This study aims to determine if enzyme supplementation, including Rizolipase, can improve the quality of life for these patients. The trial focuses on evaluating the effects of a combination of enzymes, including amylase, protease, and rizolipase, administered as a capsule called Nortase®.

At a glance

Trial Name
The Pancreatic Enzymes after Gastrectomy Trial
Main Objective
To determine if enzyme supplementation improves quality of life after gastrectomy
Participants
Patients aged 18 or older who have undergone total or partial gastrectomy
Drug Tested
Nortase® (containing amylase, protease, and rizolipase)
Treatment Duration
Up to 6 months
Primary Endpoint
Disease-specific quality of life at 6 months (EORTC-QLQ-C30 physical sub-score)
Dosage
Maximum daily dose: 15 units; Maximum total dose: 2700 units
Administration Route
Oral

What is RIZOLIPASE?

RIZOLIPASE is an active substance that belongs to a group of medications known as pancreatic enzymes. It is one of the key components in a medication called Nortase®, which also contains two other enzymes: amylase and protease. These enzymes work together to help digest food in patients who have undergone a gastrectomy, which is the surgical removal of all or part of the stomach.

Medical Conditions Treated

RIZOLIPASE, as part of the Nortase® medication, is primarily used to treat patients who have undergone a gastrectomy (total or partial removal of the stomach). After this surgery, patients often experience difficulties in digesting food properly, which can lead to various nutritional problems and a decreased quality of life. The enzyme combination in Nortase®, including RIZOLIPASE, aims to improve digestion and overall well-being in these patients.

How RIZOLIPASE Works

RIZOLIPASE is a type of lipase, which is an enzyme that helps break down fats in the food we eat. When combined with amylase (which breaks down carbohydrates) and protease (which breaks down proteins), RIZOLIPASE helps to compensate for the reduced digestive function in patients who have had their stomach removed or partially removed. By taking these enzymes with meals, patients may be able to digest their food more effectively, potentially leading to better nutrition and improved quality of life.

Current Clinical Trial

RIZOLIPASE is currently being studied in a clinical trial called "The Pancreatic Enzymes after Gastrectomy Trial". This trial aims to investigate whether taking enzyme supplements (including RIZOLIPASE) with every meal after gastrectomy can improve the quality of life for patients six months after their surgery.

Eligibility for the Trial

To participate in this clinical trial, patients must meet certain criteria:

Inclusion Criteria:

  • Have undergone a gastrectomy (total or partial)
  • Be 18 years of age or older

Exclusion Criteria:

  • Already have an indication for pancreas enzyme therapy
  • Have had a gastrectomy with palliative intention (meaning the surgery was done to relieve symptoms rather than to cure)
  • Have Stage IV gastric cancer (advanced stage cancer that has spread to distant parts of the body)
  • Have malnutrition from other causes
  • Have a life expectancy of less than 12 months
  • Have known lactose intolerance or hereditary galactose intolerance
  • Are taking alpha-glucosidase inhibitors (a type of medication used to treat diabetes)
  • Have acute pancreatitis or an acute episode of chronic pancreatitis (inflammation of the pancreas)
  • Have a known hypersensitivity (allergy) to molds or any other ingredient in Nortase®

How RIZOLIPASE is Administered

RIZOLIPASE, as part of Nortase®, is taken orally in the form of a hard capsule. In the clinical trial, patients are instructed to take the enzyme supplement with every meal. The maximum daily dose mentioned in the trial is 15 capsules, with a total maximum dose of 2700 capsules over a 6-month period.

Potential Benefits

The main goal of using RIZOLIPASE and other pancreatic enzymes after gastrectomy is to improve the patient's disease-specific quality of life. This is being measured in the clinical trial using a standardized questionnaire (EORTC-QLQ-C30) that assesses various aspects of a patient's physical well-being. By potentially improving digestion, these enzymes may help patients better absorb nutrients from their food, potentially leading to improved overall health and well-being.

Precautions and Contraindications

While RIZOLIPASE and other pancreatic enzymes can be beneficial for many patients after gastrectomy, there are some situations where they should not be used:

  • If you have a known allergy to molds or any ingredients in Nortase®
  • If you have acute pancreatitis or an acute episode of chronic pancreatitis
  • If you have lactose intolerance or hereditary galactose intolerance
  • If you are taking alpha-glucosidase inhibitors

Always consult with your healthcare provider before starting any new medication, including pancreatic enzyme supplements like those containing RIZOLIPASE.

Questions people often ask

Conditions where Rizolipase is being studied

Each condition opens its own overview and trial list

Trials with Rizolipase

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).